In a featured article on the impact of Big Data for Life Sciences companies, Saama CSO – Sagar Anisingaraju shared his insights on importance of integrating disparate data sources at all stages of the value chain — discovery, clinical trials, regulatory approval, marketing, and distribution, to derive maximum value from Real World Evidence. The article highlighted by biotech’s # 1 magazine GEN, further lists advantages of Saama’s Life Sciences offerings – Clinical Development Analytics (CDA) and Real World Evidence Analytics (RWEA).
These advanced analytics Solutions analyze long term longitudinal data on unmet needs, clinical trial inefficiencies and market access. Actionable outcomes are generated across the food chain.
Read the full article here.